HT
ESPR

HAP Trading’s Esperion Therapeutics ESPR Stock Holding History

HAP Trading’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-225,000
Closed -$78.8K – 760
2024
Q4 		$78.8K Hold
225,000
– – 0.01% 420
2024
Q3 		$50.6K Hold
225,000
– – 0.01% 470
2024
Q2 		$208K Hold
225,000
– – 0.02% 279
2024
Q1 		$309K Buy
225,000
+100,000
+80% +$243K 0.04% 236
2023
Q4 		$234K Sell
125,000
-170,200
-58% -$221K 0.04% 274
2023
Q3 		$30 Hold
295,200
– – ﹤0.01% 1014
2023
Q2 		$1.57K Sell
295,200
-23,300
-7% -$32.5K ﹤0.01% 1017
2023
Q1 		$37K Buy
318,500
+291,200
+1,067% +$1.5M 0.01% 606
2022
Q4 		$25K Buy
+27,300
New +$195K ﹤0.01% 900
2022
Q1 		– Sell
-14,900
Closed -$3K – 2387
2021
Q4 		$3K Buy
14,900
+2,600
+21% +$20.8K ﹤0.01% 2314
2021
Q3 		$15K Buy
+12,300
New +$179K ﹤0.01% 1884
2017
Q2 		– Sell
-47,200
Closed -$31K – 1009
2017
Q1 		$31K Buy
+47,200
New +$1.08M ﹤0.01% 761

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

HAP Trading's ESPR Position: Q3 2018 in Review

HAP Trading sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 10,597 shares — an estimated $487K sold.

HAP Trading first reported a position in ESPR in Q2 2018 and held it in 1 quarter. The position peaked at $415K in Q2 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • HAP Trading reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • HAP Trading sold 10,597 Esperion Therapeutics shares in Q3 2018, an estimated $487K.
  • HAP Trading first reported a position in Esperion Therapeutics in Q2 2018 and held it in 1 quarter.
  • HAP Trading's Esperion Therapeutics position peaked at $415K in Q2 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on HAP Trading's 13F filing for Q3 2018, filed 9 Nov 2018.